Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.76 USD
+0.25 (2.94%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $8.74 -0.02 (-0.23%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Brokerage Reports
Theravance Biopharma, Inc. [TBPH]
Reports for Purchase
Showing records 21 - 40 ( 212 total )
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for TBPH 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri Continues To Chug Along as Theravance Approaches Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
2Q Sales Came Below Expectations But Yupelri?s Growth Indicators Remain Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri''s Indicators All Point Up; PT Up to $20; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department